Home
LDNNow on social media
Campaign News
Studies and Research
Request for Case Study
Clinical Trials
Case Studies
Pre-Clinical Studies
Articles of Interest
Dr Zagon and Dr McLaughlin’s Work
LDN Side Effects
Articles and Press
Petitions
LDN and OGF Pharmacies
LDNNow Blog
Guestbook
Contact
   
 


By using LDN, we are modulating the OGF-OGFr axis which helps balances the immune system and works towards slowing down disease progression.  Research is showing that for some diseases there aren’t enough OGF receptors for the OGF to attach on to. Other diseases have too many receptors and not enough opioids.  Either creates an imbalance which needs correcting. Please see this link for further information which we will be updating as more studies are published furthering our understanding about using this novel therapy.

Understanding the OGF-OGFr axis as a homeostatic regulator of proliferation has substantial implications for maintaining human health and treatment of disease. More..


MULTIPLE SCLEROSIS

Astrocyte Proliferation is Regulated by the OGF-OGFr Axis In Vitro and in Experimental Autoimmune Encephalomyelitis (2013)

OGF arrests the progression of clinical disease and spinal cord pathology in established EAE (2012)

Prevention and diminished expression of EAE by LDN or OGF: Therapeutic implications for multiple sclerosis (2011)

T lymphocyte proliferation is suppressed by the OGF-OGFr axis: Implication for the treatment of autoimmune diseases (2011)

B lymphocyte proliferation is suppressed by the OGF-OGFr axis: Implication for the treatment of autoimmune diseases (2011)


CANCER

The OGF-OGFr axis is a physiological determinant of cell proliferation in diverse human cancers (2009)


ANGIOGENSIS

Opioid growth factor modulates angiogenesis (2012)


BREAST CANCER

Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers (2014)

Successful Treatment of Triple Negative Breast Cancer by Modulation of the OGF-OGFr Axis (2013)


HEAD AND NECK CANCERS

Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck (2012)

Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice (2003)


LIVER (HHC)

The OGF-OGFr axis regulates cell proliferation of human hepatocellular cancer (2010)


NEUROBLASTOMA

Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor (1999)


OVARIAN CANCER

Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers (2014)

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice (2011)

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin (2011)

Cell proliferation of human ovarian cancer is regulated by the OGF-OGFr axis (2009)


PANCREATIC CANCER

OGF and the treatment of human pancreatic cancer: a review (2014)

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer (2008)

Prevention and delay in progression of human pancreatic cancer by stable over expression of the OGF receptor (2008)


THYROID CANCER

Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis (2009)

https://www.ncbi.nlm.nih.gov/pubmed/19014324